Company insider dossier

Aurinia Pharmaceuticals Inc insider intelligence

AUPH filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
81/100

Conviction accumulation

54/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
4 Jun 2026

Investment committee read

Conviction accumulation

Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.

Research constructive setups

Evidence in favour

  • 5 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 8 named insiders rather than one filing source.

Decision risks

  • The latest qualifying filing is more than 30 days old.
Conviction81Conviction accumulation
Confidence54Developing
Named insiders8participating in the tape
Controlled events5directional common-share events
Acquisition value$12.5Mnormalized amount
Disposal value$0normalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

17.2314.7812.329.877.41 Acquisition · 2 Jun 2026 · $3.1MAcquisition · 1 Jun 2026 · $5.2MAcquisition · 1 Jun 2026 · $1.5KAcquisition · 29 May 2026 · $4.0MAcquisition · 29 May 2026 · $35.3KAcquisition · 18 May 2026 · Not reportedAcquisition · 18 May 2026 · Not reportedAcquisition · 18 May 2026 · Not reported
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
15.85 USD
One-week move
+6.5%
Four-week move
+0.4%
Fair-value gap
+60.6%
Trend signal
Active
Relative strength
-4.9

Directional balance

Controlled event mix

100.0%acquisition
Acquisition events
5
Disposal events
0
Net value
$12.5M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

225 May
801 Jun
008 Jun
015 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug

Named participants

Insider conviction by person

TANG, KEVINDirector, Chief Executive Officer, 10% Owner815 events
BAILEY, JEFFREY ALLENDirector500 events
COLE, RYANChief Operating Officer500 events
GOETZ, KATHLEENDirector500 events
HEARNE, MICHAEL SChief Financial Officer500 events
JOHNSON, CRAIG ADirector500 events
NOVA, TINA SUSANDirector500 events
ROBERTSON, STEPHEN P.Chief Legal Officer500 events

Evidence quality

Security and transaction context

Common equity8
Equity compensation0
Options and derivatives7
Other securities0

Role architecture

Who is participating

CEO and chair6
Director4
Other executive3
Finance leadership2

Transaction evidence

Auditable AUPH filing ledger

Showing 1 to 15 of 15.

BAILEY, JEFFREY ALLENDirector
AcquisitionOptions and derivatives
23931 sharesDirector Stock Option (right to buy)
Not reportedContext evidence
GOETZ, KATHLEENDirector
AcquisitionOptions and derivatives
23931 sharesDirector Stock Option (right to buy)
Not reportedContext evidence
JOHNSON, CRAIG ADirector
AcquisitionOptions and derivatives
23931 sharesDirector Stock Option (right to buy)
Not reportedContext evidence
NOVA, TINA SUSANDirector
AcquisitionOptions and derivatives
23931 sharesDirector Stock Option (right to buy)
Not reportedContext evidence
TANG, KEVINDirector, Chief Executive Officer, 10% Owner
AcquisitionCommon equity
206005 sharesCommon Shares
$3.1MDirectional evidence
TANG, KEVINDirector, Chief Executive Officer, 10% Owner
AcquisitionOptions and derivatives
10000 sharesShort Put Options (potential obligation to buy)
$16.5KContext evidence
TANG, KEVINDirector, Chief Executive Officer, 10% Owner
AcquisitionCommon equity
343521 sharesCommon Shares
$5.2MDirectional evidence
TANG, KEVINDirector, Chief Executive Officer, 10% Owner
AcquisitionCommon equity
99 sharesCommon Shares
$1.5KDirectional evidence
TANG, KEVINDirector, Chief Executive Officer, 10% Owner
AcquisitionCommon equity
262682 sharesCommon Shares
$4.0MDirectional evidence
TANG, KEVINDirector, Chief Executive Officer, 10% Owner
AcquisitionCommon equity
2299 sharesCommon Shares
$35.3KDirectional evidence
COLE, RYANChief Operating Officer
AcquisitionCommon equity
116144 sharesCommon Stock
Not reportedContext evidence
COLE, RYANChief Operating Officer
AcquisitionOptions and derivatives
70230 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
HEARNE, MICHAEL SChief Financial Officer
AcquisitionOptions and derivatives
70230 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
HEARNE, MICHAEL SChief Financial Officer
AcquisitionCommon equity
116144 sharesCommon Stock
Not reportedContext evidence
ROBERTSON, STEPHEN P.Chief Legal Officer
AcquisitionCommon equity
115541 sharesCommon Stock
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context